48 HOUR FLASH SALE -- 20% Off the Following Stem Cell Reports
"Your level of income will rarely exceed your level of knowledge."
Market intelligence can position you to approach investors for fundraising, increase sales from stem cell products, and decrease risks of new product development. Invest in yourself and your company today, so you can make smarter decisions, faster.
This 204-page global strategic report reveals key metrics impacting the cord blood banking industry, including rates of clinical trials, scientific publications, grants, patents, product launches, new market entrants, and more. It analyzes strategic partnerships, deal-making within the industry, and investments flowing into the industry, including contributions from ABS Capital Partners, KKR & Company, Bay City Capital, GTCR LLC, and Excalibur. In addition to analyzing opportunities for storage of cord blood and cord tissue products, it considers opportunities for storage of other perinatal stem cell types (placental, amniotic, and more). Importantly, it includes a 40-question, 52-page survey completed by 600+ recent and expectant parents that reveals how to effectively educate parents, prioritize your marketing budget, and understand why parents bank publicly, privately, or not at all. Access to these market insights are vital, because the cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.
Stem Cell Research Products – Opportunities, Tools, and TechnologiesThis global strategic report evaluates opportunities from across the stem cell product spectrum. It tracks traditional market metrics, which include trend rate data for stem cell clinical trials, scientific publications, grants, patents, product launches, new market entrants, acquisitions, and more. However, it also tracks social analytics, which are metrics derived from social media sites, search engines, and online advertising platforms. The significance of social analytics is that they reveal individual user behavior on a topic, as well as aggregate group activity. Importantly, they allow you to identify the frequency at which online users are searching for, posting about, and seeking out stem cell product information. Another distinctive feature of this report is an end-user survey of 289 researchers worldwide that identify stem cells as their core research focus. These survey findings reveal functional needs, technical preferences, and key factors influencing buying decisions among stem cell researchers.
To date, more than 30,000 scientific publications have been published about mesenchymal stem cells (MSCs) and the number released per year has increased for 26 years straight. There are also nearly 500 active MSC clinical trials underway worldwide. Importantly, this global report tracks traditional market metrics, which include trend rate data for MSC clinical trials, scientific publications, grants, patents, product launches, new market entrants, acquisitions, and more. However, it also tracks new social analytics, which are metrics derived from social media sites, search engines, and online advertising platforms. Social analytics identify that MSCs are more frequently cited than any other stem cell type and Google Trend data reveals MSC searches to be nearly twice as common as the next most popular stem cell type. Claim access to these insider insights to optimally position yourself within the MSC marketplace.
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry ReportSince the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is increasing with double-digit growth. In addition, 22% of stem cell researchers now report using iPSCs within a research project. A distinctive feature of this report is an end-user survey of 273 researchers (131 U.S. / 143 International) that identify having iPSCs as a research focus. These survey findings reveal functional needs, technical preferences, and key factors influencing buying decisions among iPSC researchers. With Cynata Therapeutics announcing news this week that it is positioned to launch the world's first clinical trial involving an allogeneic iPSC-derived product, you need to be well-informed about opportunities and risks within the global iPSC marketplace.
*Enter the code "FLASH" at checkout to claim your 20% discount. And remember to act soon, because this offer expires in 48 hours.*
Be Great!
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.p.s. Have questions about this offer or difficulty activating the coupon code? Hit "reply" to this email to reach me. I would be more than happy to help you.
|
|
|
